The persistent hyperendemic TF prevalence observed in some districts, despite 8–11 years of the SAFE strategy, may reflect a different trachoma epidemiology than what is observed in areas which reach elimination within predicted time lines.24 The gene discussed is TF; the disease is inclusion conjunctivitis.